Identification of Death-Associated Protein Kinases Inhibitors Using Structure-Based Virtual Screening
journal contributionposted on 26.11.2009 by Masako Okamoto, Kiyoshi Takayama, Tomoko Shimizu, Kazuhiro Ishida, Osamu Takahashi, Toshio Furuya
Any type of content formally published in an academic journal, usually following a peer-review process.
Death-associated protein kinases (DAPKs) function in the early stages of eukaryotic programmed cell death. DAPKs are now emerging as targets for drug discovery in novel therapeutic approaches for ischemic diseases in the brain, heart, kidney, and other organs. Using a structure-based virtual screening approach, we discovered potent and selective DAPKs inhibitors. 6 was found to be the most potent inhibitor with enzyme selectivity (IC50 = 69 nM for DAPK1).